145 related articles for article (PubMed ID: 3128351)
1. Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.
Smit Sibinga CT; Schulting PJ; Notebomer J; Das PC; Marrink J; vd Meer J
Blut; 1988 Mar; 56(3):111-6. PubMed ID: 3128351
[TBL] [Abstract][Full Text] [Related]
2. Development of a heat-treated factor VIII/von Willebrand factor concentrate prepared from heparinized plasma.
Palmer DS; Ganz PR; Perkins H; Rosborough D; Rock G
Thromb Haemost; 1990 Jun; 63(3):392-402. PubMed ID: 2119525
[TBL] [Abstract][Full Text] [Related]
3. Development and small-scale production of a severely heated factor VIII concentrate.
Knevelman A; de Wit HJ; Potstra P; vd Does JA
Vox Sang; 1994; 66(2):89-95. PubMed ID: 8184598
[TBL] [Abstract][Full Text] [Related]
4. Controlled pore glass factor VIII concentrate: influence of heat treatment.
Ockelford PA; Benny AG; Berry EW; Johns AS; Woodfield DG
Pathology; 1987 Jan; 19(1):56-7. PubMed ID: 3108838
[TBL] [Abstract][Full Text] [Related]
5. Severely heated therapeutic factor VIII concentrate of high specific activity.
Winkelman L; Owen NE; Evans DR; Evans H; Haddon ME; Smith JK; Prince PJ; Williams JD; Lane RS
Vox Sang; 1989; 57(2):97-103. PubMed ID: 2506696
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluation of a factor VIII concentrate heat-treated to inactivate HTLV-III/LAV viruses. Favourable effects of heating on the von Willebrand factor.
Mazurier C; de Romeuf C; Parquet-Gernez A; Jorieux S; Goudemand M
Vox Sang; 1987; 52(4):265-71. PubMed ID: 3114955
[TBL] [Abstract][Full Text] [Related]
7. Preparation of intermediate-purity factor VIII concentrate by direct gel filtration of cryoprecipitate.
Teh LC
Vox Sang; 1993; 65(4):251-7. PubMed ID: 8310677
[TBL] [Abstract][Full Text] [Related]
8. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease.
Tuddenham EG; Lane RS; Rotblat F; Johnson AJ; Snape TJ; Middleton S; Kernoff PB
Br J Haematol; 1982 Oct; 52(2):259-67. PubMed ID: 6812613
[TBL] [Abstract][Full Text] [Related]
9. Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
McGrath KM; Thomas KB; Herrington RW; Turner PJ; Taylor L; Ekert H; Schiff P; Gust ID
Med J Aust; 1985 Jul; 143(1):11-3. PubMed ID: 2989666
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of a heat treated antihaemophilic cryoprecipitate.
Skjønsberg OH; Gravem K; Kierulf P; Godal HC
Thromb Res; 1987 Mar; 45(5):625-34. PubMed ID: 3109063
[TBL] [Abstract][Full Text] [Related]
11. Clearance of cryoprecipitated factor VIII in canine hemophilia A.
Aufderheide WM; Skinner SF; Kaneko JJ
Am J Vet Res; 1975 Apr; 36(4 Pt.1):367-70. PubMed ID: 1124873
[TBL] [Abstract][Full Text] [Related]
12. Effect of virucidal heat treatment on proteins in human factor VIII concentrates.
Thomas KB; McGrath KM; Taylor M; Young IF; Herrington RW; Schiff P
Transfusion; 1988; 28(1):8-13. PubMed ID: 3124306
[TBL] [Abstract][Full Text] [Related]
13. Influence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
Benny AG; Ockelford PA; Johns AS; Scott RH; Woodfield DG; Berry EW
J Clin Pathol; 1988 Sep; 41(9):945-7. PubMed ID: 3142936
[TBL] [Abstract][Full Text] [Related]
14. Heat-treated NHS factor VIII concentrate in the United Kingdom--a preliminary study.
Colvin BT; Ainsworth M; Machin SJ; Mackie IJ; Smith JK; Winkelman L; Haddon ME
Clin Lab Haematol; 1986; 8(2):85-92. PubMed ID: 3015481
[TBL] [Abstract][Full Text] [Related]
15. A highly purified factor VIII:c concentrate prepared from cryoprecipitate by ion-exchange chromatography.
Burnouf T; Burnouf-Radosevich M; Huart JJ; Goudemand M
Vox Sang; 1991; 60(1):8-15. PubMed ID: 1905084
[TBL] [Abstract][Full Text] [Related]
16. [Factor VIII:C activity during heat inactivation of viruses in cryoprecipitates].
Grgicević D; Flego I; Marchiotti I; Lupret L; Rajninger-Miholić M
Lijec Vjesn; 1990; 112(7-8):212-5. PubMed ID: 2127297
[TBL] [Abstract][Full Text] [Related]
17. Characterization of F VIII concentrates produced by two methods incorporating double virus inactivation.
Branović K; Gebauer B; Trescec A; Benko B
Appl Biochem Biotechnol; 1998 Feb; 69(2):99-111. PubMed ID: 9513991
[TBL] [Abstract][Full Text] [Related]
18. [Comparative study of concentrated blood derivatives of factor VIII].
Baklaja R; Miletić V; Stajić M; Cvetković V; Grozdanić V
Bilt Hematol Transfuz; 1984; 12(2):91-103. PubMed ID: 6441567
[TBL] [Abstract][Full Text] [Related]
19. Factor VIII: C (FVIII: C) recovery and half-life after infusion of steam-treated high purity factor VIII concentrate in severe hemophilia A--comparison of one-stage assay, two-stage assay and a chromogenic substrate assay.
Hellstern P; Kiehl R; Miyashita C; Schwerdt H; von Blohn G; Köhler M; Büttner M; Wenzel E
Thromb Haemost; 1986 Dec; 56(3):353-9. PubMed ID: 3105109
[TBL] [Abstract][Full Text] [Related]
20. HIV infection in Norwegian haemophiliacs: the prevalence of antibodies against HIV in haemophiliacs treated with lyophilized cryoprecipitate from volunteer donors.
Evensen SA; Ulstrup J; Skaug K; Frøland SS; Glomstein A; Rollag H
Eur J Haematol; 1987 Jul; 39(1):44-8. PubMed ID: 3115823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
